# 2026-10873: FDA Draft Aims to Slash Animal Tests for New Cancer Drugs

2026-10873, Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-01, effective Submit either electronic or written comments on the draft guidance by July 31, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-10873
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-10873
- Title: Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 32402
- Published: 2026-06-01
- Effective: Submit either electronic or written comments on the draft guidance by July 31, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
- Comments close: 2026-07-31
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Draft Aims to Slash Animal Tests for New Cancer Drugs

## Summary

The FDA is rolling out a new draft guide to help cancer drug makers speed up safety testing for biologic and conjugated medicines. This plan cuts down on extra animal testing and uses smarter methods learned during the COVID-19 pandemic. Drug developers should send their feedback by July 31, 2026, to shape the final rules and save time and money in bringing new cancer treatments to patients.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a draft guidance for industry entitled "Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products." When finalized, this guidance will assist sponsors in implementing streamlined approaches for general toxicology, for nonclinical safety assessments of certain oncology pharmaceuticals. The guidance is intended to facilitate drug development for biological products and conjugated products for the treatment of cancer while avoiding unnecessary animal use. The recommendations in this draft guidance are informed by data analysis of general toxicology studies and practices developed during the COVID-19 pandemic to reduce use of non-human primates.

## Effects PRIA read

- Faster safety testing for cancer drugs: benefit, medium. The FDA published a draft guidance to help sponsors of biologic and conjugated oncology products streamline nonclinical safety testing so drug development can move faster and avoid unnecessary studies. The draft is open for comments and stakeholders should submit feedback by July 31, 2026.
- Reduced use of animals and primates: benefit, medium. The draft guidance recommends approaches to avoid unnecessary animal use and to reduce use of non-human primates in nonclinical safety studies, using practices developed during the COVID-19 pandemic.
- Primary focus on 3‑month toxicology: benefit, low. When finalized, the guidance will give recommendations for general toxicology studies with a primary focus on 3-month toxicology studies for certain oncology biologic and conjugated products.
- Guidance excludes impurities and excipients: cost, low. The draft guidance does not address nonclinical safety assessments for impurities or excipients, so sponsors must rely on other guidance or regulations for those elements of product development.
- Opportunity to comment on costs: benefit, low. FDA will consider comments on costs or cost savings the guidance may generate, consistent with Executive Order 14192; submit comments by July 31, 2026 to ensure consideration before the final guidance.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-10873 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/01/2026-10873/oncology-pharmaceuticals-streamlined-nonclinical-safety-studies-for-biologics-and-conjugated)
- [2026-10873 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-01/pdf/2026-10873.pdf)

## Related
- [Previous: 2026-10868, Designation of New Grantee; Foreign-Trade Zone 181; Akron/Canton, Ohio](https://policyrisk.com/federal-register/2026-10868)
- [Next: 2026-10874, Sunshine Act Meetings](https://policyrisk.com/federal-register/2026-10874)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-10873 (as of 2026-06-08).